TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer

RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
被引用次数：1839 相关文章

TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

RS Herbst, D Prager, R Hermann… - Journal of …, 2005 - mdanderson.elsevierpure.com
Purpose: Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer …

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

RS Herbst, D Prager, R Hermann… - Journal of Clinical …, 2005 - europepmc.org
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer …

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

RS Herbst, D Prager, R Hermann… - Journal of Clinical …, 2005 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Erlotinib is a potent reversible
HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent …

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

RS Herbst, D Prager, R Hermann, L Fehrenbacher… - NaN, 2005 - citedrive.com
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

[引用][C] TRIBUTA: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

RS HERBST, D PRAGER, D RAMIES… - Journal of clinical …, 2005 - pascal-francis.inist.fr
TRIBUTA: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and
paclitaxel chemotherapy in advanced non-small-cell lung cancer CNRS Inist Pascal-Francis …

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - pubmed.ncbi.nlm.nih.gov
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer …

TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

RS Herbst, D Prager… - Journal of …, 2005 - utsouthwestern.elsevierpure.com
Purpose: Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer …

[引用][C] TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

H RS - J Clin Oncol, 2005 - cir.nii.ac.jp
TRIBUTE : a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin
and paclitaxel chemotherapy in advanced non-small-cell lung cancer | CiNii Research CiNii …